Post‑procedural topical care aims to accelerate recovery of the skin barrier and may also modulate longer‑term appearance outcomes. Pro‑Xylane is described in the abstract as a potent anti‑aging ingredient; however, evidence is limited on whether combining Pro‑Xylane with other actives such as niacinamide and panthenol in a comprehensive post‑procedure regimen produces synergistic benefits for both barrier repair and anti‑aging outcomes following laser treatment. This study was undertaken to assess such a regimen, branded REGENMEDIC, in the context of PicoWay laser procedures.
The trial is reported as a randomized controlled study with a total planned duration of 112 days. The full abstract states that assessments were made both in the early post‑procedure window and over the longer follow‑up period. The source text available to this summary is truncated and does not include full procedural details, statistical methods, or outcome data.
According to the abstract, 88 Chinese female participants were enrolled and randomized. No additional demographic details (age ranges, baseline skin types, inclusion/exclusion criteria) are provided in the available source excerpt. The study appears in Lasers in Medical Science (2026) and was conducted by authors affiliated with L'Oréal Dermatological Beauty, La Roche‑Posay, and associated research centers in China and France.
The test intervention comprised the REGENMEDIC cream (described as an anti‑aging cream) and REGENMEDIC serum (anti‑aging serum). These products contain a combination of Pro‑Xylane, niacinamide, and panthenol, together with other active agents not itemized in the portion of the abstract provided.
The control arm received a standard care regimen consisting of a standard cream. The abstract specifies that the REGENMEDIC products were applied following PicoWay laser treatment; the precise application schedule, dosing, and any concomitant measures (for example, cleansing, sunscreen, or other supportive care) are not detailed in the available text.
The abstract describes two temporal outcome domains:
Early skin barrier repair: assessed during the initial 14 days following a single application of the REGENMEDIC cream after PicoWay laser treatment.
Anti‑aging endpoints: measures over the study period included skin elasticity, firmness, and wrinkles. The abstract indicates these anti‑aging parameters were part of the overall evaluation but the precise timing of assessments, measurement instruments (instrumental vs clinical scales), and predefined primary versus secondary endpoints are not specified in the provided text.
The source excerpt available here is truncated before reporting numerical results, effect sizes, statistical analyses, safety or tolerability findings, or study conclusions. Therefore, this summary is limited to reporting the study design, interventions, population size, duration, and outcome domains as stated in the abstract. Specific efficacy outcomes, comparative results between REGENMEDIC and standard care, and any adverse event information were not reported in the accessible text and could not be inferred.
The publication citation in the source: Lasers Med Sci. 2026 Sep 3;41(1):212. DOI 10.1007/s10103-026-04995-1. PubMed identifier (PMID) 42686896.
Authors listed in the abstract include Huijuan Liu and multiple coauthors affiliated with the Medical Department, L'Oréal Dermatological Beauty; Research and Innovation Center, L'Oréal China; La Roche‑Posay; and North Asia L'Oréal Dermatological Beauty. Institutional affiliations are specified in the source. Contact information for a corresponding author is provided in the full PubMed entry but was not reproduced here.
From the available abstract text, the study addresses an important clinical question about optimizing post‑laser topical care using a combination product containing Pro‑Xylane, niacinamide, and panthenol. However, because the abstract text provided is incomplete and omits outcome data and statistical findings, clinicians and researchers should consult the full published article (DOI 10.1007/s10103-026-04995-1) to review detailed methods, quantitative results, safety data, and authors' conclusions before changing practice or making product recommendations.